Cargando…

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer

Darolutamide (NUBEQA(®)) is an oral androgen receptor inhibitor (ARi) that is approved for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT) and docetaxel. In a pivotal trial, darolutamide plus ADT and docetaxel was superior...

Descripción completa

Detalles Bibliográficos
Autor principal: Lee, Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517889/
https://www.ncbi.nlm.nih.gov/pubmed/37542594
http://dx.doi.org/10.1007/s11523-023-00984-4